EP 43

Antibody-Drug Conjugate

Antibody-Drug Conjugates (ADCs) are a type of cancer treatment that combines a monoclonal antibody with a cytotoxic payload. This episode explores the history, mechanics, and cutting-edge technology behind ADCs, including their potential to revolutionize oncology. With 21 approved ADCs worldwide and a market projected to hit over $30 billion by 2028, ADCs are a rapidly growing field. This episode delves into the complexities of ADC design, including the balancing act between stability and release, and the role of AI in accelerating ADC development.

Antibody-Drug ConjugateCancer TreatmentOncologyAI in Medicine

play_arrowListen to episode

Key Concepts

Antibody-Drug Conjugate (ADC) Design

ADCs consist of three parts: a monoclonal antibody, a cytotoxic payload, and a chemical linker.
The antibody is engineered to target a specific protein on cancer cells.
The payload is designed to kill the cancer cell.
The linker must be stable in the bloodstream but release the payload once inside the cancer cell.

Linker Technology

Linkers can be cleavable or non-cleavable.
Cleavable linkers are designed to break apart in response to specific triggers, such as enzymes or acidic environments.
Non-cleavable linkers are more stable but may not release the payload as effectively.

Payload Technology

Payloads can be microtubule inhibitors, DNA-damaging agents, or topoisomerase I inhibitors.
Each type of payload has its own mechanism of action and potential side effects.

Bystander Effect

The bystander effect is a phenomenon where the payload can leak out of the targeted cell and kill neighboring cancer cells.
This effect can be beneficial in killing cancer cells that are not directly targeted by the ADC.

AI in ADC Development

AI can be used to design more effective and safer ADCs.
AI can predict the structure and binding of antibodies, as well as the stability and toxicity of linkers and payloads.

Episode Summary

check_circleThe concept of a 'magic bullet' in cancer treatment was first proposed by Paul Ehrlich in 1907.
check_circleAntibody-Drug Conjugates (ADCs) are a type of cancer treatment that combines a monoclonal antibody with a cytotoxic payload.
check_circleADCs consist of three parts: a monoclonal antibody, a cytotoxic payload, and a chemical linker.
check_circleThe antibody is engineered to target a specific protein on cancer cells, while the payload is designed to kill the cell.
check_circleThe linker is a critical component that must be stable in the bloodstream but release the payload once inside the cancer cell.
check_circleThe bystander effect is a phenomenon where the payload can leak out of the targeted cell and kill neighboring cancer cells.
check_circleADCs have a long history of development, with the first attempts dating back to the 1950s and 1960s.
check_circleThe first approved ADC, Mylotarg, was approved in 2000 but withdrawn in 2010 due to toxicity issues.
check_circleModern ADCs have improved linkers and payloads, leading to increased efficacy and reduced toxicity.
check_circleAI is playing a significant role in accelerating ADC development, with the potential to design more effective and safer ADCs.
check_circleADCs are being explored for use in autoimmune diseases, such as rheumatoid arthritis and psoriasis.

Full Transcript

Discussion

Join the discussion — sign in to leave a comment.